SPOTLIGHT: Booming vaccine biz boosts Sanofi income


Sanofi-Aventis says that the booming vaccine market will boost its income from the sector to 15 percent of its annual revenue in coming years, up from 10 percent. Report

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.